ESMO 2025: Overall Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress held in Berlin, Germany, was host to a prostate, penile, and testicular cancers proffered paper session. Dr. Neal Shore presented the overall survival (OS) results …

Source link